Literature DB >> 11021891

Combination treatment for hepatitis C is not being given.

G R Foster, R Chapman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2000        PMID： 11021891      PMCID： PMC1118696     

Source DB:  PubMed          Journal:  BMJ        ISSN： 0959-8138


× No keyword cloud information.
  4 in total

Review 1.  EASL International Consensus Conference on Hepatitis C. Paris, 26-28, February 1999, Consensus Statement. European Association for the Study of the Liver.

Authors: 
Journal:  J Hepatol       Date:  1999-05       Impact factor: 25.083

2.  Community prevalence of hepatitis C viraemia: a polymerase chain reaction study.

Authors:  R Sallie; R King; E Silva; C Tibbs; P Johnson; R Williams
Journal:  J Med Virol       Date:  1994-06       Impact factor: 2.327

3.  Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT)

Authors:  T Poynard; P Marcellin; S S Lee; C Niederau; G S Minuk; G Ideo; V Bain; J Heathcote; S Zeuzem; C Trepo; J Albrecht
Journal:  Lancet       Date:  1998-10-31       Impact factor: 79.321

4.  Clinical outcomes after transfusion-associated hepatitis C.

Authors:  M J Tong; N S el-Farra; A R Reikes; R L Co
Journal:  N Engl J Med       Date:  1995-06-01       Impact factor: 91.245
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.